v3.26.1
Industry Segment Information (Tables)
 3 Months Ended
Apr. 05, 2026
Segment Reporting [Abstract]  
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Segment cost of revenue131,574 156,753 119,321 135,190 
Segment selling, general and administrative expenses94,668 90,192 87,094 89,891 
Segment research and development expenses31,624 26,206 28,269 25,271 
Segment operating income$103,979 $76,122 180,101 $105,711 $74,015 179,726 
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177 
Acquisition and divestiture-related costs(282)(2,541)
Disposition of businesses and assets, net5,074 — 
Transformation costs(794)— 
Significant litigation matters and settlements(69)(10,586)
Significant environmental matters— 1,208 
Restructuring and other(10,675)(3,239)
Interest and other expense, net(25,894)(19,848)
Income from continuing operations before income taxes$49,992 $52,382 
Schedule of Depreciation [Table Text Block]
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Life Sciences$9,905 $7,185 
Diagnostics9,560 6,846 
Corporate510 691 
Total depreciation expense$19,975 $14,722